Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program

BACKGROUND: Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Here, we performed an integrated analysis of malignancy events from the tofacitinib phase 3 UC clinical development program (excluding nonmelanoma skin cancer [NMSC]). METHODS: Dat...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Inflamm Bowel Dis
Asıl Yazarlar: Lichtenstein, Gary R, Rogler, Gerhard, Ciorba, Matthew A, Su, Chinyu, Chan, Gary, Pedersen, Ronald D, Lawendy, Nervin, Quirk, Daniel, Nduaka, Chudy I, Thorpe, Andrew J, Panés, Julian
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2020
Konular:
Clinical Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8128409/
https://ncbi.nlm.nih.gov/pubmed/32766762
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ibd/izaa199
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller